HealthMine survey: 74% of people say activity trackers help them cope with heart condition

Consumers are beginning to embrace mobile tools for heart health—but not enough. A January HealthMine survey of 501 consumers with known heart disease and/or risk found that just 27% of people are using an activity tracker. Only 16% say they are using their tracker to manage their heart condition/risk. Yet 74% of those who do use an activity tracker report the device is helping them cope with their heart condition.

27% of Americans are living with some form of cardiovascular disease (according to the American Heart Association), and 47% of Americans have at least one of the three key risk factors for heart conditions: high blood pressure, high cholesterol or smoking. Mobile devices and apps can provide a convenient way to help track risk factors and disease, including tools for self-data collection, fitness, diet, and more.

Overall, HealthMine found that 31% of those with a heart condition/risk are using some type of mobile health tool to manage their condition/risk. Here's what they are using:

HealthMine's survey also found that 20% of respondents received a fitness or health-related gift for the holidays, and 10% say they were gifted a wearable activity tracker.

As for the 69% of consumers with heart problems who aren't using mobile health tools to manage their condition/risk, 36% say they prefer "traditional" methods to manage their health, and 34% say they don't know which device/app to use. Another 20% say they don't own a mobile device, and 15% find mobile health tools too confusing.

Bryce Williams, CEO and President of HealthMine said: "Being connected to your health data can make a difference." He continued: "Millions of wearable fitness tracking devices will be incorporated into wellness programs over the next few years. But they need to tie into a larger, clinically-based strategy to help consumers know where they stand with their health, what they need to do and stay motivated to do it."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis